文献速递心境障碍会诊联络精神医学

抗抑郁药治疗初级保健中抑郁障碍的真实世界效果:基于人群的队列研究

Real-world effects of antidepressants for depressive disorder in primary care: population-based cohort study.
PubMed 文献 · Br J Psychiatry · 2024-12-05

基于QResearch数据库纳入673 177名新诊断抑郁的英国成人,比较各抗抑郁药与氟西汀在2个月和12个月的可接受性、耐受性、安全性及疗效。真实世界中抗抑郁药可接受性低、耐受性与安全性中至高、疗效小至中等;仅在大数据集分析时真实世界与随机对照试验估计相似。

要点

  • 2个月可接受性61.4%、耐受性94.4%、安全性54.5%,PHQ-9降至12.3;12个月分别为12.3%、87.5%、28.8%、12.9。
  • 短期和长期三环类、米氮平和曲唑酮在多数结局上差于氟西汀。
  • 西酞普兰短期可接受性优于氟西汀(aOR 0.95;99% CI 0.92, 0.97),舍曲林耐受性较低(aOR 1.12;99% CI 1.06, 1.18)。

核心结论

  • 真实世界中抗抑郁药显示低可接受性、中至高耐受性和安全性、小至中等疗效。
  • 仅当使用大型数据集分析时,真实世界与随机对照试验估计结果相似,否则结果有分歧。

研究设计与样本

  • 基于QResearch数据库的队列研究,纳入673 177名新记录抑郁诊断并暴露于英国许可抗抑郁药者。
  • 女性57.1%,平均年龄42.8岁(s.d. 17.7),平均基线PHQ-9 17.1(s.d. 5.0)(中度至重度抑郁)。
  • 采用逻辑回归计算校正比值比(aOR)及99% CI,以氟西汀为对照,评估2个月和12个月结局。
  • 使用比值比之比(ROR)及95% CI比较真实世界与随机对照试验估计。

主要发现

  • 2个月可接受性61.4%、耐受性94.4%、安全性54.5%,PHQ-9降至12.3(s.d. 6.5)。
  • 12个月可接受性12.3%、耐受性87.5%、安全性28.8%,PHQ-9为12.9(s.d. 6.8)。
  • 短期和长期三环类、米氮平和曲唑酮在多数结局上差于氟西汀。
  • 西酞普兰短期可接受性优于氟西汀(aOR 0.95;99% CI 0.92, 0.97),舍曲林耐受性较低(aOR 1.12;99% CI 1.06, 1.18),西酞普兰和舍曲林安全性较低(aOR分别为1.17和1.25)。
  • 长期西酞普兰可接受性更好(aOR 0.78;99% CI 0.76, 0.81)、疗效更好(应答和缓解aOR均为1.12),但耐受性更差(aOR 1.09;99% CI 1.06, 1.13)、安全性更差(aOR 1.12;99% CI 1.08, 1.16)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antidepressants' effects are established in randomised controlled trials (RCTs), but not in the real world. AIMS: To investigate real-world comparative effects of antidepressants for depression and compare them with RCTs. METHOD: We performed a cohort study based on the QResearch database. We included people with a newly recorded diagnosis of depression, exposed to licensed antidepressants in the UK. We assessed all-cause dropouts (acceptability), dropouts for adverse events (tolerability), occurrence of at least one adverse event (safety), and response and remission on the Patient Health Questionnaire (PHQ)-9 (effectiveness) at 2 and 12 months. Logistic regressions were used to compute adjusted-odds ratio (aOR) with 99% CIs, assessing the associations between exposure to each antidepressant against fluoxetine (comparator) and outcomes of interest. We compared estimates from the real world with RCTs using ratio-of-odds ratio (ROR) with 95% CI. RESULTS: A total of 673 177 depressed people were studied: females 57.1%, mean age 42.8 (s.d. 17.7) years, mean baseline PHQ-9 17.1 (s.d. 5.0) (moderately severe depression). At 2 months, antidepressant acceptability was 61.4%, tolerability 94.4%, safety 54.5%, PHQ-9 decreased to 12.3 (s.d. 6.5). At 12 months, acceptability was 12.3%, tolerability 87.5%, safety 28.8%, PHQ-9 12.9 (s.d. 6.8). In the short and long term, tricyclics, mirtazapine and trazodone were worse than fluoxetine for most outcomes; citalopram had better acceptability than fluoxetine (aOR 0.95; 99% CI 0.92, 0.97), sertraline had lower tolerability (aOR 1.12; 99% CI 1.06, 1.18), and both citalopram and sertraline had lower safety (aOR 1.17 and 1.25, respectively). In the long term, citalopram had better acceptability (aOR 0.78; 99% CI 0.76, 0.81) and effectiveness (aOR 1.12 for both response and remission), but worse tolerability (aOR 1.09; 99% CI 1.06, 1.13) and safety (aOR 1.12; 99% CI 1.08, 1.16). Observational and randomised data were similar for citalopram and sertraline, while there was some difference for drugs less prescribed in the real world. CONCLUSIONS: Antidepressants showed low acceptability, moderate-to-high tolerability and safety, and small-to-moderate effectiveness in the real world. Real-world and RCT estimates showed similar findings only when the analyses were carried out using large datasets; otherwise, the results diverged.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. De Crescenzo F, De Giorgi R, Garriga C, et al. Real-world effects of antidepressants for depressive disorder in primary care: population-based cohort study. Br J Psychiatry. 2024. PMID: 39632598. doi:10.1192/bjp.2024.194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。